We use cookies to provide you with a better experience. By continuing to browse the site you are agreeing to our use of cookies in accordance with our Cookie Policy.
Accept
Home » BIOLINERX IN-LICENSES TWO ADDITIONAL DRUG CANDIDATES FROM TEL AVIV UNIVERSITY AND THE TECHNION AND ACHIEVES 2005 GOALS
BIOLINERX IN-LICENSES TWO ADDITIONAL DRUG CANDIDATES FROM TEL AVIV UNIVERSITY AND THE TECHNION AND ACHIEVES 2005 GOALS
January 30, 2006
Leading Drug Development Company Continues In-Licensing Strategy and Advances
Pipeline toward Clinical Trials BioLineRx, Ltd., Israel's leading specialized
drug development company, today announced that it has signed two license agreements
for the development and commercialization of BL-2050, for the treatment of peripheral
vascular disease (PVD) and BL-2060, a novel antibiotic.
